Witjes - Figure 53
BCG vs TCTh
FIG. 53: Another, randomized and controlled trial in almost 200 patients compared 1 year of BCG with 1 year of chemohyperthermia with mitomycin.[44] After 24 months, recurrence-free survival was 82% with chemohyperthermia compared to 65% with BCG, and these were intermediate- and high-risk patients. Again, progression rates were low. So this is an option to keep in mind, and it is at least as effective as BCG.
References
Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69:1046−52 http://dx.doi.org/10.1016/j.eururo.2016.01.006